Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.

2 Mar 2010

Archimedes Pharma raises GBP65 million in new funding

Archimedes Pharma, the leading specialty pharma company, today announced that it has raised GBP65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes also announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon.

2 Mar 2010

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

Celsion Corporation today announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care and Albert Einstein College of Medicine in New York City, will serve as Principal Investigator for the study.

2 Mar 2010

3M and PCTS to globally market innovative automated hand hygiene compliance solution

3M and Patient Care Technology Systems, a subsidiary of Consulier Engineering, Inc., today announced that they have signed an agreement to bring a state-of-the-art automated hand hygiene compliance solution to healthcare customers globally.

27 Feb 2010

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

EKOS Corporation announced today that Dr. David W. Newell, Co–Executive Director, Swedish Neuroscience Institute (Seattle, WA) presented a SNI clinical study known as ‘SLEUTH’ (Safety of Lysis with Ultrasound in the Treatment of Intracerebral (ICH) and Intraventricular Hemorrhage (IVH) at the American Heart Association International Stroke Conference (San Antonio, TX).

26 Feb 2010

Supelco launches Ascentis Express Peptide ES-C18 HPLC columns

Supelco, a division of Sigma-Aldrich®, announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core™ particle design. This column design exhibits very high column efficiency, providing a stable, reversed phase packing with a pore structure and pore size that is optimized for reversed-phase HPLC separations of peptides and polypeptides.

26 Feb 2010

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Impax Laboratories, Inc. today reported its strongest financial results in its history due to record sales from its Global products sales channel.

25 Feb 2010

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere’s Convertible Promissory Note to May 26, 2010.

25 Feb 2010

Scientists one step closer to innovative drug delivery

A team of scientists led by Dr Simon Richardson at the University of Greenwich has got a step closer to one of the holy grails of drug delivery.

25 Feb 2010

Zcube joins Mission Bay Capital Fund with $1M investment

Mission Bay Capital, LLC, has added a new limited partner to its first venture fund, bolstering the fund's ability to invest in promising bioscience companies emerging from the University of California.

25 Feb 2010

BD Biosciences initiates next-generation flow cytometer

BD Biosciences, a segment of BD, announced today the launch of the BD FACSAria™ III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.

From BD (Becton, Dickinson and Company) 23 Feb 2010

Centric Health Resources and CHT to create sustainable healthcare system for Americans

St. Louis-based Centric Health Resources, Inc. joined the Center for Health Transformation (CHT) a high-impact collaboration of private and public sector leaders committed to creating a 21st Century Intelligent Health System that saves lives and money for all Americans.

23 Feb 2010

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

When head and neck tumors - from sinus tumors to acoustic neuromas attached to the hearing and balance nerve at the base of the skull - are located in close proximity to such sensitive areas such as the brain and eyes, they are particularly dangerous due to possible brain injury, visionary risk or hearing loss.

23 Feb 2010

DURECT, Nycomed amend POSIDUR Development and License Agreement

DURECT Corporation announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR™ (also known as SABER™-Bupivacaine or OPTESIA™), an investigational drug for the treatment of post-surgical pain.

23 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

BioFlorida launches The BioFlorida Institute to create programs to improve science education

BioFlorida, the statewide trade association founded in 1997 to advance Florida’s bioscience industry, has approved a plan to launch The BioFlorida Institute, a not-for-profit foundation focused on education, professional development and industry resources. The Institute, working in partnership with BioFlorida, will create programs to improve science education and support bioscience entrepreneurs and scientists throughout the state.

19 Feb 2010

Nuvo Research reports net income in fourth-quarter, driven by FDA approval of Pennsaid

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the year and the fourth quarter ended December 31, 2009.

19 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

Echo Therapeutics makes significant advance in designing Symphony tCGM device

Echo Therapeutics, Inc., a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced today that the Company has made a significant advance in the product design of its Symphony tCGM device and that it has developed its next generation electronic component package.

19 Feb 2010

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company’s revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.

18 Feb 2010

Drug Delivery News and Research

Further Reading

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Archimedes Pharma raises GBP65 million in new funding

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

3M and PCTS to globally market innovative automated hand hygiene compliance solution

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

Supelco launches Ascentis Express Peptide ES-C18 HPLC columns

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Scientists one step closer to innovative drug delivery

Zcube joins Mission Bay Capital Fund with $1M investment

BD Biosciences initiates next-generation flow cytometer

Centric Health Resources and CHT to create sustainable healthcare system for Americans

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

DURECT, Nycomed amend POSIDUR Development and License Agreement

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioFlorida launches The BioFlorida Institute to create programs to improve science education

Nuvo Research reports net income in fourth-quarter, driven by FDA approval of Pennsaid

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Echo Therapeutics makes significant advance in designing Symphony tCGM device

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Developing a best-in-class, end-to-end CMC platform eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo